Skip to main content

6 Result(s)

within Yvonne Summers Remove this filter Biomedicine, general Remove this filter

and

  1. No Access

    Article

    Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index

    Pembrolizumab is licensed for the treatment of pre-treated and PD-L1 positive non-small cell lung cancer (NSCLC), but response is heterogeneous. In this context, the Lung Immune Prognostic Index (LIPI) has bee...

    Ana Ortega-Franco, Clare Hodgson, Haseem Raja, Mathew Carter… in Targeted Oncology (2022)

  2. Article

    Open Access

    Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

    Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chem...

    Colin R. Lindsay, Emily C. Shaw, David A. Moore, Doris Rassl… in British Journal of Cancer (2021)

    Download PDF (1507 KB) View Article

  3. Article

    Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Francesca Chemi, Dominic G. Rothwell, Nicholas McGranahan, Sakshi Gulati… in Nature Medicine (2020)

    Download PDF (669 KB) View Article

  4. No Access

    Article

    Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

    Approximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery with curative intent will relapse within 5 years1,2. Detection of circulating tumor cells (CTCs) at the time o...

    Francesca Chemi, Dominic G. Rothwell, Nicholas McGranahan, Sakshi Gulati… in Nature Medicine (2019)

  5. Article

    Open Access

    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

    We investigated selumetinib (AZD6244, ARRY-142886), an oral, potent, and highly selective, allosteric MEK1/2 inhibitor, plus platinum-doublet chemotherapy for patients with advanced/metastatic non-small cell l...

    Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau… in British Journal of Cancer (2017)

    Download PDF (475 KB) View Article

  6. No Access

    Article

    Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study

    Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS)...

    Maya Gottfried, Jaafar Bennouna, Igor Bondarenko, Jean-Yves Douillard… in Targeted Oncology (2017)